SPONSOR

Ruijin Hospital

Total Trials

Recruiting

Phases

Phase 2, Phase 1, Phase 1, Phase 2, Phase 3

Conditions studied: Gastrointestinal Malignancies Gastric Cancer Stage IV Peritoneal Metastases Essential Tremor Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy Gastrointestinal Tumors Health Personnel B-cell Non-Hodgkin Lymphoma Carotid Atherosclerotic Plaque Ascending Aortic Dissection

Ruijin Hospital is a clinical research sponsor with 30 registered studies on ClinicalTrials.gov, of which 30 are actively recruiting participants. Research covers conditions including Gastrointestinal Malignancies, Gastric Cancer Stage IV, Peritoneal Metastases, Essential Tremor.

The trial portfolio spans Phase 2, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Ruijin Hospital

How many clinical trials has Ruijin Hospital sponsored?

ClinicalMetric currently tracks 30 clinical trials sponsored by Ruijin Hospital, of which 30 are actively recruiting participants. These trials cover conditions including Gastrointestinal Malignancies, Gastric Cancer Stage IV, Peritoneal Metastases. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Ruijin Hospital research focus on?

Ruijin Hospital clinical trials span Gastrointestinal Malignancies, Gastric Cancer Stage IV, Peritoneal Metastases, Essential Tremor, Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Ruijin Hospital clinical trial?

To participate in a Ruijin Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ruijin Hospital trials with current recruitment status updated daily.

Ruijin Hospital

Frequently Asked Questions — Ruijin Hospital

Clinical Trials by Ruijin Hospital

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Non-Invasive Neuromodulation for Essential Tremor: Long-Term Safety and Effectiveness Study

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Prospective Management of Plaque Instability With Statins and Extra Folic Acid

Retrograde Ascending Dissection: Intraluminal Aortic Therapy

Genotype-guided Treatment in Newly Diagnosed PTCL

CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial

(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer

a Feasibility Study of iHD-SRT for BM

Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Endoscopic Ultrasound-guided Fine-needle Aspiration of Solid Pancreatic Lesions With Rapid Staining of Cytological Smears Followed by Whole Slide Scanning and Artificial Intelligence Diagnosis: A Prospective, Multicenter Study.

A Fast, Quiet, Artificial Intelligence-based PET/MR Solution for Paediatric Diseases

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.

Efficacy and Safety of tACS for Depression: a Multicenter RCT Study

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Cell Free DNA in Mature B-cell Lymphoma

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease